Introduction
============

A novel technique of creating an alternative route through an *ab interno* approach *via* implantation of a collagen implant XEN (Allergan, Irvine, CA, USA) has been described in an attempt to overcome different complications that are seen in glaucoma filtration surgery ([@r1], [@r2]). The XEN implant has been approved by the European Medicines Agency and the U.S. Food and Drug Administration for surgical treatment of glaucoma. The XEN gel stent is a 6-mm hydrophilic tube with a 45-µm lumen size, composed of a porcine collagen-derived gelatin crosslinked with glutaraldehyde. This gelatin stent provides *ab interno* approach and bypasses the natural drainage pathways, which often become obstructed and cause elevated intraocular pressure (IOP). The ideal stent placement should be 2.0 mm of exposed implant in the subconjunctival space, 1.0 mm in the anterior chamber and 3.0 mm tunneled through the sclera. However, some cases of stent exposure have been described in the literature ([@r3]), as well as dislocation of XEN gel into the anterior chamber ([@r4]), XEN gel internal ostium occlusion ([@r5]), suprachoroidal bleeding after XEN gel implantation ([@r6]), and postoperative hypotony associated with a shallow anterior chamber and choroidal effusions after surgery ([@r7]). As with all new devices, there is a lack of experience and knowledge about its long-term results in terms of efficacy, technique and complications ([@r8]).

Case Report
===========

This report presents a case of subconjunctival fragmentation of the XEN gel implant three months after the surgery. Consent for publication of this case report was obtained from the patient. A 70-year-old male was treated and followed-up for primary open angle glaucoma in the Glaucoma Unit, Department of Ophthalmology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia. The patient underwent successful phacoemulsification and intraocular lens implantation two years before. Before surgery, the IOP was 26 mm Hg in the right eye and 24 mm Hg in the left eye despite maximum tolerated topical treatment with three IOP lowering medications (bimatoprost/timolol fixed combination once in the evening and dorzolamide twice a day). Since IOP was poorly controlled, XEN implantation was offered to the patient for both eyes, and the patient consented to the procedure offered. Surgical steps for XEN implantation in both eyes included the following: 0.2 mg/mL of mitomycin C injected subconjunctivally in the area of planned XEN implantation, marking the conjunctiva 3 mm from the limbus superonasally. The anterior chamber was filled with Healon GV (Abbot Medical Optics, Inc., Santa Ana, CA, USA) and inferotemporal 1.8-mm clear corneal incision was created through which the preloaded inserter needle (double beveled 27-gauge) was directed across the anterior chamber in the opposite side to penetrate the angle under gonioscopic view. Once the needle was visible in the subconjunctival space, it was rotated toward 12 o'clock and the stent was gently injected into the subconjunctival space. Healon GV was irrigated out of the anterior chamber at the end of surgical procedure. Intraoperative mild intracameral hemorrhage occurred but it was promptly resolved with irrigation-aspiration procedure. Due to overlong intrachamber part of the implant, the blunt tweezer was used to relocate the implant by scleral approach. The implant immediately began shunting fluid from the anterior chamber to the subconjunctival space with an initial extended bleb due to the gentle diffuse dispersion of aqueous humor into the non-dissected conjunctiva.

Postoperative treatment included a combination of dexamethasone and tobramycin administered 4 times daily for 15 days and then slowly reduced over the next 2 weeks.

The surgery was successful in both eyes. Slit lamp examination confirmed proper positioning of the XEN implant and successful bleb formation. IOP was 14 mm Hg in the right eye and 15 mm Hg in the left eye (with no IOP lowering medications) one and two months after the surgery.

Three months after the surgery, at the regular follow-up visit, an uncommon adverse event was found. We noticed three fragments of the subconjunctival part of the XEN gel in the patient's left eye, as shown by slit-lamp and anterior segment optical coherence tomography ([Fig. 1a and b](#f1){ref-type="fig"}). The IOP was 14 mm Hg despite the fact that there was no bleb formation in the area of previous XEN implantation. Gonioscopic view showed the intracameral part of the implant to be correctly located inside the Schlemm's canal ([Fig. 2](#f2){ref-type="fig"}).

![Subconjunctival fragments of the XEN gel stent: (a) slit lamp photograph; (b) anterior segment optical coherence tomography.](acc-58-767-f1){#f1}

![Gonioscopic view of the anterior chamber part of the XEN gel stent.](acc-58-767-f2){#f2}

Discussion and Conclusions
==========================

Our report suggests that subconjunctival fragmentation of the XEN gel implant can occur after successful placement and functional bleb formation. The implant is a hydrophilic, non-inflammatory subconjunctival gelatin stent. The gelatin stent swells and becomes soft when hydrated, which helps maintain its intended position as it adapts to the shape of the surrounding tissues to create permanent channel from the anterior chamber to the subconjunctival space ([@r9]). This occurs within 2 minutes after implantation. Relocating the implant by scleral approach in case of short subconjunctival part (less than 2 mm) and long intracameral part (more than 1 mm) is an ordinary procedure during surgery. The patient denied rubbing the eye or any other possible incident during those three months. For this reason, relocating the implant by scleral approach with blunt tweezers should not lead to the risk of stent fragmentation, especially because of its gelatinous properties.

However, this case report presents an uncommon adverse event detected at regular follow-up visit. In this case, after fragmentation of the XEN gel, the implant does not utilize subconjunctival filtration for aqueous outflow. Subconjunctival filtration creates a non-physiologic route for aqueous outflow, which is the basis of traditional trabeculectomy and aqueous shunt glaucoma surgery ([@r5], [@r6]).

In conclusion, our report suggests a new potential complication of the XEN gel stent implantation. The mechanism of its occurrence remains unclear. At this moment, we are unaware of any report on subconjunctival XEN gel fragmentation available in the literature. This could imply clinical significance of this case report as the first report on the subconjunctival XEN gel fragmentation at three-month follow-up of successful and effective XEN gel implantation.
